TORONTO, ONTARIO--(Marketwired - May 13, 2015) - Spectral Medical Inc. ("Spectral" or the "Company") (TSX:EDT)(OTCQX:EDTXF), a Phase III company developing the first treatment for patients with septic shock guided by a companion diagnostic, today announced that at the annual and special meeting (the "Meeting") of shareholders of the Corporation ("Shareholders") that was held yesterday, all six nominees for the board were elected, the voting results of which are as follows:
| Director | Number and percentage of common shares of the Corporation ("Shares") represented in person or by proxy and entitled to vote at the Meeting that were voted For | Number and percentage of Shares represented in person or by proxy and entitled to vote at the Meeting that were WITHELD from voting | |
| Anthony Bihl III | 113,585,904 (99.93%) | 76,096 (0.07%) | |
| Kevin Giese | 109,427,585 (96.27%) | 4,234,415 (3.73%) | |
| Guillermo Herrera | 113,560,543 (99.91%) | 101,457 (0.09%) | |
| Paul M. Walker | 113,586,904 (99.93%) | 75,096 (0.07%) | |
| William Stevens | 113,580,602 (99.93%) | 81,398 (0.07%) | |
| Koichiro Takeshita | 113,551,293 (99.90%) | 110,707 (0.10%) |
At the Meeting, Shareholders also re-approved the stock option plan of the Corporation. Full details of the foregoing are contained in the Report of Voting Results for the Meeting which has been filed on Sedar at www.Sedar.com.
About Spectral
Spectral is a Phase III company seeking U.S. FDA approval for its lead theranostics product for the treatment of endotoxemic septic shock. Toraymyxin™ (PMX) is a therapeutic hemoperfusion device that removes endotoxin, a main trigger of sepsis, from the bloodstream. Directed by the Company's Endotoxin Activity Assay (EAA™), the only FDA cleared diagnostic for the risk of developing sepsis, Spectral's EUPHRATES trial is the world's only active and most innovative Phase III study for a medical device in the area of septic shock.
PMX has been approved for therapeutic use in Japan and Europe, and has been used on more than 100,000 patients to date. In March 2009, Spectral obtained the exclusive development and commercial rights in the U.S. for PMX, and in November 2010, signed an exclusive distribution agreement for this product in Canada. Approximately 350,000 patients are diagnosed with septic shock in North America each year, representing a greater than $3 billion market opportunity for Spectral.
Spectral is listed on the Toronto Stock Exchange under the symbol EDT, and on the OTCQX under the symbol EDTXF. For more information please visit www.spectraldx.com.
Forward-looking statement
Information in this news release that is not current or historical factual information may constitute forward-looking information within the meaning of securities laws. Implicit in this information, particularly in respect of the future outlook of Spectral and anticipated events or results, are assumptions based on beliefs of Spectral's senior management as well as information currently available to it. While these assumptions were considered reasonable by Spectral at the time of preparation, they may prove to be incorrect. Readers are cautioned that actual results are subject to a number of risks and uncertainties, including the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of Spectral to take advantage of business opportunities in the biomedical industry, the granting of necessary approvals by regulatory authorities as well as general economic, market and business conditions, and could differ materially from what is currently expected.
The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this statement.
Contact Information:
Anthony Businskas
Executive Vice President and CFO
416-626-3233 ext. 2200
tbusinskas@spectraldx.com
Ali Mahdavi
Capital Markets & Investor Relations
416-962-3300
am@spinnakercmi.com